Kymera (NASDAQ: KYMR) director’s 10b5-1 trades total 9,494 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kymera Therapeutics director Bruce Booth reported option exercises and share sales in Kymera Therapeutics, Inc. common stock. Booth exercised stock options to acquire 6,359 shares at an exercise price of $14.18 per share, then sold 6,359 directly held shares in open-market trades around $90 per share.
Additional sales of 2,750 shares and 385 shares were made by investment funds Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., with which Booth is associated and where he disclaims Section 16 beneficial ownership except for any pecuniary interest. These transactions, totaling 9,494 shares sold, were executed under Rule 10b5-1 trading plans adopted in December 2025, indicating they were pre-arranged rather than timed discretionarily.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 9,494 shares ($854,539)
Net Sell
8 txns
Insider
Booth Bruce
Role
Director
Sold
9,494 shs ($855K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 2,200 | $0.00 | -- |
| Exercise | Common Stock | 2,200 | $14.18 | $31K |
| Sale | Common Stock | 2,200 | $89.95 | $198K |
| Sale | Common Stock | 2,750 | $90.10 | $248K |
| Sale | Common Stock | 385 | $90.10 | $35K |
| Exercise | Stock Option (Right to Buy) | 4,159 | $0.00 | -- |
| Exercise | Common Stock | 4,159 | $14.18 | $59K |
| Sale | Common Stock | 4,159 | $89.97 | $374K |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,641 shares (Direct);
Common Stock — 2,200 shares (Direct);
Common Stock — 3,899,917 shares (Indirect, See footnote)
Footnotes (1)
- This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.95 to $90.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2), (3) and (5). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.95 to $90.00 inclusive. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.05 to $90.145 inclusive. These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. Fully vested and exercisable.
Key Figures
Options exercised: 6,359 shares
Exercise price: $14.18 per share
Total shares sold: 9,494 shares
+5 more
8 metrics
Options exercised
6,359 shares
Stock options exercised at $14.18 per share
Exercise price
$14.18 per share
Stock Option (Right to Buy) for Kymera common stock
Total shares sold
9,494 shares
Net shares sold across direct and indirect holdings
Direct sale prices
$89.95–$90.10
Weighted average price range for direct open-market sales
Indirect sale price
$90.10 per share
Representative price for Atlas Venture fund sales
Atlas Venture Fund X holding
3,899,917 shares
Shares of Kymera common stock held after transactions
Atlas Opportunity Fund holding
674,956 shares
Kymera shares held after transactions by AVOF
Option expiration
June 15, 2032
Expiration date for exercised stock options
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy), weighted average price, Section 16 beneficial ownership, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Section 16 beneficial ownership regulatory
"disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X"
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What insider transactions did Kymera (KYMR) director Bruce Booth report?
Bruce Booth reported exercising options for 6,359 Kymera shares at $14.18 and selling 9,494 shares in total around $90 per share. Some sales were from his direct holdings and others from affiliated Atlas Venture funds.
What options did Bruce Booth exercise in Kymera Therapeutics (KYMR)?
Booth exercised fully vested stock options for 6,359 Kymera shares at a $14.18 exercise price. These options, described as “Stock Option (Right to Buy),” had an expiration date in June 2032 and were already fully exercisable at the time.